New study: Canadian women on hormone therapy show healthier diet, activity, and sleep patterns

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

A cross-sectional analysis of more than 10,000 women, published June 17, 2026 in Menopause, the journal of The Menopause Society, found that postmenopausal women who had never used hormone therapy reported lower fruit and vegetable intake, were 19% less likely to meet strength-based physical activity guidelines, and slept fewer hours than women who used or had used hormone therapy. For Canadian patients navigating the menopause transition, the headline finding is less a reason to start hormones and more a prompt to ask a clinician whether symptom burden, lifestyle factors, and individual risk profile together make hormone therapy appropriate.

The study is the first large-scale cross-sectional analysis to examine menopause status and hormone therapy use alongside three modifiable health behaviours at once: diet, physical activity, and sleep. Researchers found that the likelihood of meeting sleep guidelines was 14% lower in never-users of hormone therapy, 26% lower in current users, and 24% lower in past users, compared with premenopausal and perimenopausal women. That last finding, that even current hormone therapy users sleep less than premenopausal women, is a reminder that hormones do not fully reverse the sleep disruption that comes with the menopause transition.

What this means in Canada

Hormone therapy products are available in Canada through Health Canada-approved formulations. Estradiol (sold in Canada as Estrace in oral form and as Estradot, Estrogel, and Climara in patch or gel form) and combined estrogen-progestogen products are listed on most provincial formularies, though coverage varies by province and by specific product. In Ontario, some hormone therapy products are covered under the Ontario Drug Benefit (ODB) program for eligible patients; in Quebec, the Régie de l'assurance maladie du Québec (RAMQ) covers select formulations for patients who meet clinical criteria; in British Columbia, coverage falls under the BC PharmaCare program. Patients in Alberta can check the Alberta Drug Benefit List under the Alberta Health Care Insurance Plan (AHCIP).

The Society of Obstetricians and Gynaecologists of Canada (SOGC) has issued guidance supporting the use of hormone therapy for the management of vasomotor symptoms in appropriate candidates, noting that for healthy women under 60 or within 10 years of menopause onset, the benefits generally outweigh the risks. The SOGC has not issued a specific position statement responding to this June 2026 study. Canadian patients can access hormone therapy through family physicians, gynaecologists, and menopause specialists, as well as through virtual platforms such as Cleo (a Canadian women's-health platform), Felix, and Science & Humans (scienceandhumans.com), all of which operate under Canadian regulatory requirements. US-based platforms such as Midi Health and Hone Health do not serve Canadian patients.

What changed

Previous research on hormone therapy and lifestyle produced inconsistent results. Some studies suggested postmenopausal women became more health-conscious over time regardless of hormone use; others pointed to symptom relief from hormone therapy as a pathway to more physical activity and better sleep. This study is notable for its scale (more than 10,000 participants) and for examining all three behaviour categories together rather than in isolation.

The researchers propose two biological mechanisms for the sleep and activity gaps seen in never-users. First, elevated follicle-stimulating hormone (FSH) levels, which rise sharply after menopause in women not using hormone therapy, have been associated with poorer sleep architecture. Second, lower circulating estradiol levels in postmenopausal women are independently linked to shorter sleep duration and more fragmented sleep. Hot flashes and urogenital symptoms compound the problem and may be reduced by hormone therapy, which could partly explain why current users report somewhat better sleep than never-users, though still worse than premenopausal women.

Dr. Stephanie Faubion, medical director for The Menopause Society, was direct about the study's limits: "Healthy-user bias is likely a significant contributor. Women who choose to use hormone therapy are often more proactive in their healthcare and may systematically differ from nonusers in socioeconomic resources, access to care, and health literacy." She pointed out that this same bias led early observational studies to suggest cardiovascular benefits from hormone therapy that randomized controlled trials later failed to confirm.

What Canadian patients should know

The study is observational. It cannot tell us whether starting hormone therapy will improve a given patient's diet, activity level, or sleep. What it does show is that women who use hormone therapy tend to cluster with other health-promoting behaviours, and that clinicians should not assume hormone therapy alone accounts for better health outcomes in that group.

For Canadian patients already on hormone therapy (estradiol, combined estrogen-progestogen, or local vaginal estrogen), the findings are not a reason to change anything. For patients considering hormone therapy primarily for vasomotor symptoms or sleep disruption, the study adds to a body of evidence suggesting symptom control may have downstream effects on activity and rest, though the causal direction remains uncertain.

Provincial coverage differences matter practically. A patient in Ontario on ODB may pay little or nothing for a covered estradiol patch, while a patient in a province without equivalent formulary coverage could pay $30 to $80 CAD per month out of pocket depending on the product and dose. Patients without a family physician can access assessments through virtual menopause care platforms operating in Canada, though formulary coverage for prescriptions issued through virtual care varies by province.

Sleep duration, fruit and vegetable intake, and strength training are modifiable regardless of hormone therapy status. Canadian physical activity guidelines from the Canadian Society for Exercise Physiology recommend at least 150 minutes of moderate-to-vigorous aerobic activity per week plus muscle-strengthening activities twice a week for adults, including those in the menopause transition.

Limitations and open questions

The study design is cross-sectional, meaning it captures a single point in time and cannot establish whether hormone therapy use preceded the healthier behaviours or vice versa. The researchers acknowledge that healthy-user bias, where women who seek out and are prescribed hormone therapy already differ systematically from those who do not, is a substantial confound that observational data cannot fully correct for.

The study population and its demographic breakdown have not been described in detail in the press release, and the full paper is needed to assess how well the findings generalize to Canadian women across income levels, ethnicities, and geographic regions (urban versus rural access to care is a persistent gap in Canadian hormone care). Health Canada has not issued any guidance in response to this study, and the SOGC has not yet commented on it.

Whether hormone therapy directly changes appetite, food choices, or motivation to exercise, or whether symptom relief simply removes barriers to those behaviours, remains an open question. Randomized trial data on lifestyle behaviour outcomes as a primary endpoint in hormone therapy research are sparse.

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.